Latest News and Press Releases

$960 million deal will enhance Lilly’s existing pain management portfolio for migraine; adds potential near-term launch to its late-stage pipeline INDIANAPOLIS and CAMBRIDGE, Mass., Jan. 18, 2017 ...

CAMBRIDGE, Mass., Nov. 28, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of...

Comparison of 50 mg, 100 mg and 200 mg of lasmiditan oral tablets to placebo for the acute treatment of migraineOver 50% of the expected 2,968 migraine patients enrolled77% of patients enrolled to...

CAMBRIDGE, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today reported financial and operating results for the quarter ended September 30, 2016.  ...

CAMBRIDGE, Mass., Nov. 08, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of...

Lasmiditan (100 mg and 200 mg) oral tablets had onset of action and provided significant headache pain relief as soon as 30 minutes after dosing (p ≤ 0.004) and freedom from the most bothersome...

CAMBRIDGE, Mass., Sept. 26, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of...

1,155 patients have been randomized in GLADIATOR, with a retention rate of 74% of those patients 100 mg and 200 mg doses of lasmiditan collectively have been administered over 7,500 times in GLADIATOR...

1,155 patients have been randomized in GLADIATOR, with a retention rate of 74% of those patients 100 mg and 200 mg doses of lasmiditan collectively have been administered over 7,500 times in GLADIATOR...

100 mg and 200 mg doses of lasmiditan were more efficacious than placebo on headache pain relief at the two-hour time point (p < 0.001)100 mg and 200 mg doses of lasmiditan were more efficacious...